A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis
<br/><strong>Background: </strong>Cryptococcal meningitis is a leading cause of death in HIV-infected patients. International treatment guidelines recommend induction therapy with amphotericin B and flucytosine. This antifungal combination is most effective, but unfortunately flucy...
| Main Authors: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
Wellcome Trust
2019
|
| _version_ | 1826278562818162688 |
|---|---|
| author | Ngan, N Mai, N Tung, N Lan, N Tai, L Phu, N Chau, N Binh, T Hung, L Beardsley, J White, N Lalloo, D Krysan, D Hope, W Geskus, R Wolbers, M Nhat, L Thwaites, G Kestelyn, E Day, J |
| author_facet | Ngan, N Mai, N Tung, N Lan, N Tai, L Phu, N Chau, N Binh, T Hung, L Beardsley, J White, N Lalloo, D Krysan, D Hope, W Geskus, R Wolbers, M Nhat, L Thwaites, G Kestelyn, E Day, J |
| author_sort | Ngan, N |
| collection | OXFORD |
| description | <br/><strong>Background: </strong>Cryptococcal meningitis is a leading cause of death in HIV-infected patients. International treatment guidelines recommend induction therapy with amphotericin B and flucytosine. This antifungal combination is most effective, but unfortunately flucytosine is expensive and unavailable where the burden of disease is greatest. Where unavailable, guidelines recommend treatment with amphotericin and fluconazole, but this is less effective, with mortality rates of 40-50%. Faster rates of clearance of yeast from cerebrospinal fluid (CSF) are associated with better outcomes - improving the potency of antifungal therapy is likely to be an effective strategy to improve survival. Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal activity, appearing synergistic when combined in vitro with amphotericin, and fungicidal when combined with fluconazole. It is concentrated in the brain and macrophages, off-patent, cheap and widely available. We designed a randomized trial to deliver initial efficacy and safety data for tamoxifen combined with amphotericin and fluconazole.<br/><strong>Method: </strong>A phase II, open-label, randomized (1:1) controlled trial of tamoxifen (300mg/day) combined with amphotericin (1mg/kg/day) and fluconazole (800mg/day) for the first 2 weeks therapy for HIV infected or uninfected adults with cryptococcal meningitis. The study recruits at Cho Ray Hospital and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. The primary end point is Early Fungicidal Activity (EFA-the rate of yeast clearance from CSF), over the first two weeks of treatment. 50 patients will be recruited providing ≈80% and 90% power to detect a difference in the EFA of -0.11 or -0.13 log10CFU/ml/day, respectively.<br/><strong>Discussion: </strong>The results of the study will inform the decision to proceed to a larger trial powered to mortality. The size of effect detectable has previously been associated with reduced mortality from this devastating disease. Particular side effects of interest include QT prolongation. |
| first_indexed | 2024-03-06T23:45:47Z |
| format | Journal article |
| id | oxford-uuid:70d57fd9-df7b-4b3f-8b11-cbdf56fb27eb |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T23:45:47Z |
| publishDate | 2019 |
| publisher | Wellcome Trust |
| record_format | dspace |
| spelling | oxford-uuid:70d57fd9-df7b-4b3f-8b11-cbdf56fb27eb2022-03-26T19:39:57ZA randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitisJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:70d57fd9-df7b-4b3f-8b11-cbdf56fb27ebEnglishSymplectic Elements at OxfordWellcome Trust2019Ngan, NMai, NTung, NLan, NTai, LPhu, NChau, NBinh, THung, LBeardsley, JWhite, NLalloo, DKrysan, DHope, WGeskus, RWolbers, MNhat, LThwaites, GKestelyn, EDay, J<br/><strong>Background: </strong>Cryptococcal meningitis is a leading cause of death in HIV-infected patients. International treatment guidelines recommend induction therapy with amphotericin B and flucytosine. This antifungal combination is most effective, but unfortunately flucytosine is expensive and unavailable where the burden of disease is greatest. Where unavailable, guidelines recommend treatment with amphotericin and fluconazole, but this is less effective, with mortality rates of 40-50%. Faster rates of clearance of yeast from cerebrospinal fluid (CSF) are associated with better outcomes - improving the potency of antifungal therapy is likely to be an effective strategy to improve survival. Tamoxifen, a selective estrogen receptor modulator used to treat breast cancer, has anti-cryptococcal activity, appearing synergistic when combined in vitro with amphotericin, and fungicidal when combined with fluconazole. It is concentrated in the brain and macrophages, off-patent, cheap and widely available. We designed a randomized trial to deliver initial efficacy and safety data for tamoxifen combined with amphotericin and fluconazole.<br/><strong>Method: </strong>A phase II, open-label, randomized (1:1) controlled trial of tamoxifen (300mg/day) combined with amphotericin (1mg/kg/day) and fluconazole (800mg/day) for the first 2 weeks therapy for HIV infected or uninfected adults with cryptococcal meningitis. The study recruits at Cho Ray Hospital and the Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam. The primary end point is Early Fungicidal Activity (EFA-the rate of yeast clearance from CSF), over the first two weeks of treatment. 50 patients will be recruited providing ≈80% and 90% power to detect a difference in the EFA of -0.11 or -0.13 log10CFU/ml/day, respectively.<br/><strong>Discussion: </strong>The results of the study will inform the decision to proceed to a larger trial powered to mortality. The size of effect detectable has previously been associated with reduced mortality from this devastating disease. Particular side effects of interest include QT prolongation. |
| spellingShingle | Ngan, N Mai, N Tung, N Lan, N Tai, L Phu, N Chau, N Binh, T Hung, L Beardsley, J White, N Lalloo, D Krysan, D Hope, W Geskus, R Wolbers, M Nhat, L Thwaites, G Kestelyn, E Day, J A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title | A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title_full | A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title_fullStr | A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title_full_unstemmed | A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title_short | A randomized open label trial of tamoxifen combined with amphotericin B and fluconazole for cryptococcal meningitis |
| title_sort | randomized open label trial of tamoxifen combined with amphotericin b and fluconazole for cryptococcal meningitis |
| work_keys_str_mv | AT ngann arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT main arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT tungn arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT lann arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT tail arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT phun arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT chaun arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT binht arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT hungl arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT beardsleyj arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT whiten arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT lallood arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT krysand arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT hopew arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT geskusr arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT wolbersm arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT nhatl arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT thwaitesg arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT kestelyne arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT dayj arandomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT ngann randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT main randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT tungn randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT lann randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT tail randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT phun randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT chaun randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT binht randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT hungl randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT beardsleyj randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT whiten randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT lallood randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT krysand randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT hopew randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT geskusr randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT wolbersm randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT nhatl randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT thwaitesg randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT kestelyne randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis AT dayj randomizedopenlabeltrialoftamoxifencombinedwithamphotericinbandfluconazoleforcryptococcalmeningitis |